330194-34-8

Upstream product

• 924-44-7 glyoxylic acid ethyl ester 
• 38053-91-7 2-trimethylsilyloxy-1,3-butadiene 
• 2627-86-3 (S)-1-phenyl-ethylamine 
• 37662-06-9 ethyl <(S)-1-phenylethyl>iminoethanoate 

Downstream Products

• 330862-37-8 4,4-diethoxy-1-((S)-1-phenyl-ethyl)-piperidine-(S)-2-carboxylic acid ethyl ester 
• 330862-38-9 (1'S,2R)-4,4-diethoxy-1-(1'-phenylethyl)-piperidine-2-carboxylic acid ethyl ester 
• 1226594-71-3 (R)-8-((S)-1-phenyl-ethyl)-1,4-dioxa-8-aza-spiro[4.5]decane-7-carboxylic acid ethyl ester 
• 500688-86-8 biphenyl-4-carboxylic acid N-[(1'S,2R)-4,4-diethoxy-1-(1'-phenylethyl)piperidin-2-ylmethyl]amide 
• 330194-37-1 (1'S,2R)-4,4-diethoxy-1-(1'-phenylethyl)-2-phthalimidomethyl-piperidine 
• 330194-38-2 (1'S,2R)-4,4-diethoxy-1-(1'-phenylethyl)-2-aminomethyl-piperidine 
• 330862-39-0 (1'S,2R)-4,4-diethoxy-1-(1'-phenylethyl)-2-hydroxymethyl-piperidine 

Relevant academic research and scientific papers

BIOLOGICALLY ACTIVE AMIDES

The present invention is directed to biologically active amides which are ligands at the NPY Y5 receptor. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from certain disorders which comprises administering to the subject an amount of a compound of the subject invention. Furthermore, this invention also provides uses of a compound of the invention for the manufacture of a medicament for treating a subject suffering from certain disorders.

Method of inhibiting protein tyrosine phosphatase 1B and/or T-cell protein tyrosine phosphatase 4 and/or other PTPases with an Asp residue at position 48

The present invention provides a method of inhibiting a member of a family of Protein Tyrosine Phosphatases (PTPases, PTPs) such as PTP1B, TC-PTP, CD45, SHP-1, SHP-2, PTPα, PTPε, PTPμ, PTPδ, PTPσ, PTPζ, PTPβ, PTPD1, PTPD2, PTPH1, PTP-MEG1, PTP-LAR, and HePTP by exposing said Ptpase member by administration to a host or otherwise to at least one compound with certain structural, physical and spatial characteristics that allow for the interaction of said compound with specific residues of the active site of PTP1B and/or TC-PTP. These compounds are indicated in the management or treatment of a broad range of diseases such as autoimmune diseases, acute and chronic inflammation, osteoporosis, various forms of cancer and malignant diseases, and type I diabetes and type II diabetes, as well as in the isolation of PTPases and in elucidation or further elucidation of their biological function.

A convenient large-scale chiral synthesis of protected 2-substituted 4-oxo-piperidine derivatives

A convenient large-scale chiral synthesis of protected 2-substituted-4-oxo-piperidine derivatives is described. Hetero Diels-Alder reaction between trifluoroacetic acid-boron trifluoride activated (1-phenyl-ethylimino)acetic acid ethyl ester and 2-trimeth